login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
HALOZYME THERAPEUTICS INC (HALO) Stock News
USA
- NASDAQ:HALO -
US40637H1095
-
Common Stock
65.33
USD
+1.23 (+1.92%)
Last: 10/13/2025, 8:16:09 PM
65.33
USD
0 (0%)
After Hours:
10/13/2025, 8:16:09 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
HALO Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Demonstrates Strong Growth and Profitability
18 days ago - By: Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO): A Prime Candidate for Affordable Growth
12 days ago - By: Zacks Investment Research
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
13 days ago - By: Halozyme Therapeutics, Inc.
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
15 days ago - By: Zacks Investment Research
- Mentions:
ABBV
ANIP
ARGX
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
22 days ago - By: Benzinga
Forecasting The Future: 7 Analyst Projections For Halozyme Therapeutics
a month ago - By: Investor's Business Daily
- Mentions:
UTHR
AUPH
ARGX
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
a month ago - By: Zacks Investment Research
- Mentions:
KT
BPOP
PARR
PHIN
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
a month ago - By: Zacks Investment Research
- Mentions:
LDOS
TRU
Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion
a month ago - By: Zacks Investment Research
- Mentions:
LDOS
PAHC
PDD
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings
a month ago - By: Zacks Investment Research
- Mentions:
LDOS
TRU
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
a month ago - By: Zacks Investment Research
- Mentions:
LDOS
PAHC
PDD
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
a month ago - By: Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
a month ago - By: Zacks Investment Research
- Mentions:
TROW
CARS
Best Momentum Stock to Buy for September 3rd
a month ago - By: Zacks Investment Research
- Mentions:
ATAI
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
a month ago - By: Zacks Investment Research
- Mentions:
KMDA
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?
a month ago - By: Zacks Investment Research
How to Find Strong Buy Medical Stocks Using the Zacks Rank
a month ago - By: Zacks Investment Research
- Mentions:
SCSC
TDW
JRVR
CSW
New Strong Buy Stocks for September 3rd
a month ago - By: Zacks Investment Research
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
2 months ago - By: Yahoo Finance
- Mentions:
MS
Halozyme Therapeutics, Inc. (HALO) Hikes 2025 Guidance on ENHANZE Demand
2 months ago - By: Yahoo Finance
- Mentions:
MS
Morgan Stanley Raises PT on Halozyme Therapeutics (HALO), After Q2 Results
2 months ago - By: Halozyme Therapeutics, Inc.
Halozyme to Participate at Upcoming Investor Conferences
2 months ago - By: Zacks Investment Research
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
2 months ago - By: Investor's Business Daily
- Mentions:
ARGX
AUPH
RIGL
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
2 months ago - By: Yahoo Finance
Halozyme Therapeutics (HALO) Fell Despite Reporting Strong Earnings and Improved Guidance
2 months ago - By: Benzinga
What 7 Analyst Ratings Have To Say About Halozyme Therapeutics
2 months ago - By: Yahoo Finance
- Mentions:
UNH
CNC
OSCR
ELV
...
Solar, biotech, and health insurance stocks are rising on Friday: here's why
2 months ago - By: Yahoo Finance
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72
2 months ago - By: Yahoo Finance
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2
2 months ago - By: Zacks Investment Research
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
2 months ago - By: Zacks Investment Research
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
2 months ago - By: Zacks Investment Research
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Please enable JavaScript to continue using this application.